EAU 2014 - Poster: A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Emmanuel S. Antonarakis,¹ Adam S. Kibel,² George Adams,³ Lawrence I. Karsh,⁴ Aymen Elfiky,² Neal D. Shore,⁵ Nicholas J. Vogelzang,⁶ John M. Corman,⁷ Robert C. Tyler,⁸ Candice McCoy,⁸ Todd DeVries,⁸ Nadeem Sheikh,⁸ and Charles G. Drake,^{1, 9} at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

¹Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; ²Brigham and Women’s Hospital, Harvard University, Boston, MA; ³Urology Center of Alabama, Homewood, AL; ⁴The Urology Center of Colorado; ⁵Carolina Urologic Research Center, Myrtle Beach, SC ⁶US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; ⁷Virginia Mason Medical Center, Seattle, WA; ⁸Dendreon Corporation, Seattle, WA; ⁹Brady Urological Institute, Johns Hopkins University, Baltimore, MD

Click HERE to listen to an audio commentary by Robert Tyler, PhD, one of the authors of this study 

Click HERE to read an exclusive report by a UroToday medical writer